Menu Search
Equities

XORTX Therapeutics Inc

ANUA:DUS

XORTX Therapeutics Inc

Actions
  • Price (EUR)1.20
  • Today's Change-0.045 / -3.61%
  • Shares traded144.00
  • 1 Year change-54.73%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-2.08m
  • Incorporated2011
  • Employees3.00
  • Location
    XORTX Therapeutics Inc3710 - 33rd Street NWCALGARY T2L 2M1CanadaCAN
  • Phone+1 (403) 455-7727
  • Fax+1 (403) 607-2621
  • Websitehttps://www.xortx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.